2 Beaten-Down Stocks to Buy and Hold for a Decade
Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key is to purchase shares of robust companies, occasionally adding more, and to stick with your holdings through the highest market peaks and the most severe downturns.Despite not-so-great performances in recent years, Merck (NYSE: MRK) and Fiverr International (NYSE: FVRR) are stocks that could deliver competitive returns to patient investors in the next 10 years. Let's discover why.Merck is a leading drugmaker that develops medicines across several areas. Oncology is the company's most important field. It markets Keytruda, a cancer drug that topped the list of the world's best-selling drugs last year. Keytruda will run out of patent exclusivity in the U.S. in 2028, but Merck is developing a subcutaneous version of the cancer therapy that will extend its patent life well into the 2030s.Continue reading
Recent market volatility notwithstanding, equities generally deliver solid returns over long periods, like a decade. The key is to purchase shares of robust companies, occasionally adding more, and to stick with your holdings through the highest market peaks and the most severe downturns.
Despite not-so-great performances in recent years, Merck (NYSE: MRK) and Fiverr International (NYSE: FVRR) are stocks that could deliver competitive returns to patient investors in the next 10 years. Let's discover why.
Merck is a leading drugmaker that develops medicines across several areas. Oncology is the company's most important field. It markets Keytruda, a cancer drug that topped the list of the world's best-selling drugs last year. Keytruda will run out of patent exclusivity in the U.S. in 2028, but Merck is developing a subcutaneous version of the cancer therapy that will extend its patent life well into the 2030s.
